![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, June 22, 2020 11:54:32 AM
Gimoti nasal spray by pass the GI system and goes straight to the bloodstream which start to relief symptoms cause by Gastroparesis in minutes. Unlike the Pill form which takes hours and some times a day to work to relief symptoms, because of gastric delay empty of the stomach.
Evoke is expected to take a huge portion of the prescription market to treat Gastroparesis and Diabetic Gastroparesis disease in females. The company expect first year of sales up to 2/3 to treat the Diabetic Gastroparesis disease up to a $4 billion prescription market. Gimoti nasal spray the first of it kind to treat adult Females Diabetic Gastroparesis disease. Evoke expect millions of female worldwide to benefit from the use of Gimoti to treat their symptoms cause by diabetic gastroparesis disease.
Recent EVOK News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 11:01:20 AM
- Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI • GlobeNewswire Inc. • 06/17/2024 12:30:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 12:00:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 10:09:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 09:02:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:56:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:53:59 PM
- Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference • GlobeNewswire Inc. • 05/16/2024 08:02:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:20:33 PM
- Evoke Pharma Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/14/2024 08:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:15:18 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 05/14/2024 08:05:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:00:15 PM
- Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications • GlobeNewswire Inc. • 04/17/2024 12:30:27 PM
- Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer • GlobeNewswire Inc. • 03/21/2024 08:15:59 PM
- Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/14/2024 08:05:28 PM
- Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024 • GlobeNewswire Inc. • 03/07/2024 09:10:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:15:06 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/20/2024 09:38:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 02:00:04 PM
- Evoke Pharma Announces Closing of $7.5 Million Public Offering • GlobeNewswire Inc. • 02/14/2024 12:30:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 10:15:35 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/09/2024 10:14:30 PM
- Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million • GlobeNewswire Inc. • 02/09/2024 12:30:48 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM